NTRK3 and amyotrophic lateral sclerosis: In sum, 2B7 Fab therapy was effective in vivo in a mouse model of ALS, even when administered after disease onset, demonstrating that selective TrkC-FL agonists can be significantly and meaningfully effective in vivo, improving the key endpoints of life-span, motor function, weight, and motor neuron phenotype.